|

Mitoxantrone Hydrochloride Liposome Clinical Trials

7 actively recruiting trials

Also known as: Mitoxantrone hydrochloride liposome injection

Pipeline

Phase 2: 5Phase 1/2: 2

Top Sponsors

  • First Affiliated Hospital of Zhejiang University3
  • Sun Yat-sen University1
  • Ming-Yuan Chen1
  • Institute of Hematology & Blood Diseases Hospital, China1
  • Children's Hospital of Soochow University1

Indications

  • Cancer7
  • Relapsed/Refractory Acute Myeloid Leukaemia2
  • Acute Myeloid Leukemia2
  • Myeloid Malignancy2
  • Recurrent or Metastatic Nasopharyngeal Carcinoma1

Other7 trials

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Phase 2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Phase 1/2
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
Phase 2
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Phase 2
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.